{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:20:28Z","timestamp":1789845628128,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli studi \"Magna Graecia\" di Catanzaro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Sarcopenia is common in patients with heart failure (HF) and it is frequently associated with other comorbidities. Sarcopenia has been linked to an increased risk of major adverse cardiovascular events (MACE) in HF patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>The aim of the present study was to evaluate, in a cohort of older adult\u2019s patients affected by HF with reduced ejection fraction (HFrEF) and sarcopenia, already being treated with sacubitril\/valsartan, the effect of add-on therapy with SGLT2i on clinical, functional abilities, muscle performance and effects on quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We enrolled 147 outpatients. A simple linear regression analysis was performed to assess the correlation between the change in Cardiac Index (CI) and Short physical performance battery (SPPB) values, expressed as (\u0394) between baseline and follow-up (\u0394T0-12), and several covariates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>After 12 months of treatment, we observed an improvement in the inflammatory profile, moreover there was a reduction of the oxidative stress (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and platelets activation (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) parameters. In addition, there was a significant increase in CI and global longitudinal strain and a statistically significant improvement in cognitive function, as shown by Mini-Mental State examination (MMSE) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) score and SPPB (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Considering \u0394CI as dependent variation, \u03948-isoprotane resulted the major predictor, justifying 13.3% of its variation. When \u0394SPPB was considered as dependent variable, \u03948-Isoprostane was the main predictor of \u0394SPPB, justifying 54.6% of its variation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion and conclusions<\/jats:title>\n            <jats:p>This study demonstrated that the addition of SGLT2i to therapy leads to improvements in echocardiographic and sarcopenia-related parameters and biomarkers of oxidative stress and platelet activation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40520-025-03049-w","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T04:24:57Z","timestamp":1747628697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Gliflozines as add-on to Arni in echocardiographic, sarcopenic and oxidative stress parameters in elderly patients with chronic heart failure"],"prefix":"10.1007","volume":"37","author":[{"given":"Giuseppe","family":"Armentaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velia","family":"Cassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Magurno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Pastura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Divino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Severini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Martire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Montalcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Pujia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sciacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"3049_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16\u201331","journal-title":"Age Ageing"},{"key":"3049_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21186549","volume":"21","author":"A Lena","year":"2020","unstructured":"Lena A, Anker MS, Springer J (2020) Muscle wasting and sarcopenia in heart failure\u2014the current state of science. Int J Mol Sci 21:1\u201327","journal-title":"Int J Mol Sci"},{"key":"3049_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/ehf2.13255","volume":"8","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang J, Ni W et al (2021) Sarcopenia in heart failure: a systematic review and meta-analysis. ESC Hear Fail 8:1007\u20131017","journal-title":"ESC Hear Fail"},{"key":"3049_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/ehf2.12545","volume":"7","author":"GWPD Fonseca","year":"2020","unstructured":"Fonseca GWPD, dos Santos MR, de Souza FR et al (2020) Discriminating sarcopenia in overweight\/obese male patients with heart failure: the influence of body mass index. ESC Hear Fail 7:84\u201391. https:\/\/doi.org\/10.1002\/ehf2.12545","journal-title":"ESC Hear Fail"},{"key":"3049_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijcard.2016.07.135","volume":"222","author":"T Bekfani","year":"2016","unstructured":"Bekfani T, Pellicori P, Morris DA et al (2016) Sarcopenia in patients with heart failure with preserved ejection fraction: impact on muscle strength, exercise capacity and quality of life. Int J Cardiol 222:41\u201346. https:\/\/doi.org\/10.1016\/j.ijcard.2016.07.135","journal-title":"Int J Cardiol"},{"key":"3049_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/eurheartj\/ehs381","volume":"34","author":"S F\u00fclster","year":"2013","unstructured":"F\u00fclster S, Tacke M, Sandek A et al (2013) Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J 34:512\u2013519. https:\/\/doi.org\/10.1093\/eurheartj\/ehs381","journal-title":"Eur Heart J"},{"key":"3049_CR7","doi-asserted-by":"crossref","unstructured":"Liu Y, Su M, Lei Y et al (2023) Sarcopenia predicts adverse prognosis in patients with heart failure: A systematic review and Meta-Analysis. Rev Cardiovasc Med 24","DOI":"10.31083\/j.rcm2409273"},{"key":"3049_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/agm2.12111","volume":"3","author":"M Wang","year":"2020","unstructured":"Wang M, Hu S, Zhang F et al (2020) Correlation between sarcopenia and left ventricular myocardial mass in chronic heart failure patients. Aging Med 3:138\u2013141","journal-title":"Aging Med"},{"key":"3049_CR9","doi-asserted-by":"publisher","unstructured":"Cassano V, Miceli S, Armentaro G et al (2022) Oxidative stress and left ventricular performance in patients with different glycometabolic phenotypes. https:\/\/doi.org\/10.3390\/nu14061299. Nutrients 14:","DOI":"10.3390\/nu14061299"},{"key":"3049_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10741-021-10157-y","volume":"28","author":"M Correale","year":"2023","unstructured":"Correale M, Lamacchia O, Ciccarelli M et al (2023) Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients. Heart Fail Rev 28:733\u2013744","journal-title":"Heart Fail Rev"},{"key":"3049_CR11","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1002\/ehf2.13169","volume":"7","author":"J Butler","year":"2020","unstructured":"Butler J, Usman MS, Khan MS et al (2020) Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Hear Fail 7:3298\u20133309. https:\/\/doi.org\/10.1002\/ehf2.13169","journal-title":"ESC Hear Fail"},{"key":"3049_CR12","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/nejmoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098. https:\/\/doi.org\/10.1056\/nejmoa2206286","journal-title":"N Engl J Med"},{"key":"3049_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/nejmoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413\u20131424. https:\/\/doi.org\/10.1056\/nejmoa2022190","journal-title":"N Engl J Med"},{"key":"3049_CR14","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726","journal-title":"Eur Heart J"},{"key":"3049_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/jcsm.12048","volume":"7","author":"TK Malmstrom","year":"2016","unstructured":"Malmstrom TK, Miller DK, Simonsick EM et al (2016) SARC-F: A symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle 7:28\u201336. https:\/\/doi.org\/10.1002\/jcsm.12048","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3049_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/ageing\/afr051","volume":"40","author":"HC Roberts","year":"2011","unstructured":"Roberts HC, Denison HJ, Martin HJ et al (2011) A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing 40:423\u2013429","journal-title":"Age Ageing"},{"key":"3049_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental State. A practical method for grading the cognitive State.of patients for the clinician. J Psychiatr Res 12:189\u2013198. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6","journal-title":"J Psychiatr Res"},{"key":"3049_CR18","doi-asserted-by":"crossref","unstructured":"Pashmdarfard M, Azad A (2020) Assessment tools to evaluate activities of daily living (ADL) and instrumental activities of daily living (IADL) in older adults: A systematic review. Med J Islam Repub Iran 34","DOI":"10.47176\/mjiri.34.33"},{"key":"3049_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","volume":"17","author":"JA Yesavage","year":"1982","unstructured":"Yesavage JA, Brink TL, Rose TL et al (1982) Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 17:37\u201349. https:\/\/doi.org\/10.1016\/0022-3956(82)90033-4","journal-title":"J Psychiatr Res"},{"key":"3049_CR20","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/s1885-5857(10)70276-0","volume":"63","author":"JC Naveiro-Rilo","year":"2010","unstructured":"Naveiro-Rilo JC, Diez-Ju\u00e1rez DM, Blanco AR et al (2010) Validation of the Minnesota living with heart failure questionnaire in primary care. Rev Espa\u00f1ola Cardiol (English Ed 63:1419\u20131427. https:\/\/doi.org\/10.1016\/s1885-5857(10)70276-0","journal-title":"Rev Espa\u00f1ola Cardiol (English Ed"},{"key":"3049_CR21","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","volume":"35","author":"CP Green","year":"2000","unstructured":"Green CP, Porter CB, Bresnahan DR, Spertus JA (2000) Development and evaluation of the Kansas City cardiomyopathy questionnaire: A new health status measure for heart failure. J Am Coll Cardiol 35:1245\u20131255. https:\/\/doi.org\/10.1016\/S0735-1097(00)00531-3","journal-title":"J Am Coll Cardiol"},{"key":"3049_CR22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 16:233\u2013271. https:\/\/doi.org\/10.1093\/ehjci\/jev014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"3049_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","volume":"57","author":"RB Devereux","year":"1986","unstructured":"Devereux RB, Alonso DR, Lutas EM et al (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450\u2013458. https:\/\/doi.org\/10.1016\/0002-9149(86)90771-X","journal-title":"Am J Cardiol"},{"key":"3049_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40256-020-00445-7","volume":"21","author":"J Galo","year":"2021","unstructured":"Galo J, Celli D, Colombo R (2021) Effect of Sacubitril\/Valsartan on neurocognitive function: current status and future directions. Am J Cardiovasc Drugs 21:267\u2013270. https:\/\/doi.org\/10.1007\/s40256-020-00445-7","journal-title":"Am J Cardiovasc Drugs"},{"key":"3049_CR25","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.echo.2012.07.019","volume":"25","author":"E Altiok","year":"2012","unstructured":"Altiok E, Neizel M, Tiemann S et al (2012) Quantitative analysis of endocardial and epicardial left ventricular myocardial deformation - Comparison of strain-encoded cardiac magnetic resonance imaging with two-dimensional speckle-tracking echocardiography. J Am Soc Echocardiogr 25:1179\u20131188. https:\/\/doi.org\/10.1016\/j.echo.2012.07.019","journal-title":"J Am Soc Echocardiogr"},{"key":"3049_CR26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"key":"3049_CR27","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.jacc.2019.01.072","volume":"73","author":"MG Del Buono","year":"2019","unstructured":"Del Buono MG, Arena R, Borlaug BA et al (2019) Exercise intolerance in patients with heart failure: JACC State-of-the-Art review. J Am Coll Cardiol 73:2209\u20132225","journal-title":"J Am Coll Cardiol"},{"key":"3049_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ejhf.1320","volume":"21","author":"A van der Pol","year":"2019","unstructured":"van der Pol A, van Gilst WH, Voors AA, van der Meer P (2019) Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail 21:425\u2013435","journal-title":"Eur J Heart Fail"},{"key":"3049_CR29","doi-asserted-by":"publisher","unstructured":"Cassano V, Armentaro G, Magurno M et al (2022) Short-term effect of Sacubitril\/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure. Front Pharmacol 13. https:\/\/doi.org\/10.3389\/fphar.2022.1069828","DOI":"10.3389\/fphar.2022.1069828"},{"key":"3049_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14779072.2022.2098118","volume":"20","author":"J Adams","year":"2022","unstructured":"Adams J, Mosler C (2022) Safety and efficacy considerations amongst the elderly population in the updated treatment of heart failure: a review. Expert Rev Cardiovasc Ther 20:529\u2013541","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"3049_CR31","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nberger E, Mihaljevi\u0107 V, Steiner K et al (2023) Immunomodulatory effects of SGLT2 Inhibitors\u2014Targeting inflammation and oxidative stress in aging. Int J Environ Res Public Health 20","DOI":"10.3390\/ijerph20176671"},{"key":"3049_CR32","doi-asserted-by":"publisher","unstructured":"Nugara C, Giallauria F, Vitale G et al (2023) Effects of Sacubitril\/Valsartan on exercise capacity in patients with heart failure with reduced ejection fraction and the role of percentage of delayed enhancement measured by cardiac magnetic resonance in predicting therapeutic response: A multicentre S. Card Fail Rev 9. https:\/\/doi.org\/10.15420\/cfr.2022.13","DOI":"10.15420\/cfr.2022.13"},{"key":"3049_CR33","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1111\/dom.15249","volume":"25","author":"D Yabe","year":"2023","unstructured":"Yabe D, Shiki K, Homma G et al (2023) Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u2265\u200965 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY). Diabetes Obes Metab 25:3538\u20133548. https:\/\/doi.org\/10.1111\/dom.15249","journal-title":"Diabetes Obes Metab"},{"key":"3049_CR34","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5551\/jat.40873","volume":"25","author":"S Sugiyama","year":"2018","unstructured":"Sugiyama S, Jinnouchi H, Kurinami N et al (2018) Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes. J Atheroscler Thromb 25:467\u2013476. https:\/\/doi.org\/10.5551\/jat.40873","journal-title":"J Atheroscler Thromb"},{"key":"3049_CR35","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11096-022-01504-6","volume":"45","author":"Z Guo","year":"2023","unstructured":"Guo Z, Wang L, Yu J et al (2023) The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials. Int J Clin Pharm 45:547\u2013555","journal-title":"Int J Clin Pharm"},{"key":"3049_CR36","doi-asserted-by":"publisher","unstructured":"Gholizade M, Farhadi A, Marzban M et al (2022) Association between platelet, white blood cell count, platelet to white blood cell ratio and sarcopenia in community-dwelling older adults: focus on Bushehr elderly health (BEH) program. https:\/\/doi.org\/10.1186\/s12877-022-02954-3. BMC Geriatr 22:","DOI":"10.1186\/s12877-022-02954-3"},{"key":"3049_CR37","doi-asserted-by":"publisher","unstructured":"Liaw FY, Huang CF, Chen WL et al (2017) Higher Platelet-to-Lymphocyte ratio increased the risk of sarcopenia in the Community-Dwelling older adults. Sci Rep 7. https:\/\/doi.org\/10.1038\/s41598-017-16924-y","DOI":"10.1038\/s41598-017-16924-y"},{"key":"3049_CR38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40119-021-00242-6","volume":"10","author":"N Seecheran","year":"2021","unstructured":"Seecheran N, Grimaldos K, Ali K et al (2021) The effect of Dapagliflozin on platelet function testing profiles in diabetic patients: the EDGE pilot study. Cardiol Ther 10:561\u2013568. https:\/\/doi.org\/10.1007\/s40119-021-00242-6","journal-title":"Cardiol Ther"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-03049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-025-03049-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-03049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T04:25:00Z","timestamp":1747628700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-025-03049-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3049"],"URL":"https:\/\/doi.org\/10.1007\/s40520-025-03049-w","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the University Ethics Committee (2022.384), and written informed consent was obtained from all participants to the \u201cMAgna GraecIa evaluation of Comorbidities in patients with Heart Failure (MAGIC-HF)\u201d study (ClinicalTrials.gov identifier: NCT05915364) and by the local Ethics Committee of Calabria Region, Italy (Catanzaro, Italy, document n. 263\u201323 July 2020). This study met the standards of good clinical practice (GCP) and the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study is registered at ClinicalTrials.gov (NCT05915364). Researchers wishing to access data should contact the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}